What Kalehua Capital Management LLC reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 2106181 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 3.7M |
| ±0% |
| $17.4M |
| 12.5% |
CMPSCOMPASS Pathways plc | 819.7K | ±0% | $11.6M | 8.3% |
SRZNSurrozen, Inc. | 385.2K | ±0% | $10M | 7.2% |
ACRSAclaris Therapeutics, Inc. | 1.8M | +37.0% | $9.7M | 6.9% |
SIONSionna Therapeutics, Inc. | 197.1K | ±0% | $8.7M | 6.2% |
IKTInhibikase Therapeutics, Inc. | 3.8M | +43.0% | $7.8M | 5.6% |
PHVSPharvaris N.V. | 198.8K | ±0% | $6.9M | 4.9% |
KPTIKaryopharm Therapeutics Inc. | 685.6K | New | $6.7M | 4.8% |
SEPNSepterna, Inc. | 194.5K | ±0% | $6.5M | 4.7% |
IFRXInflaRx N.V. | 2.9M | New | $6.5M | 4.7% |
CYCNKorsana Biosciences, Inc. | 1.7M | New | $5.6M | 4% |
QUREuniQure N.V. | 79.4K | −62.5% | $3.7M | 2.6% |
LONALeonaBio, Inc. | 393.7K | ±0% | $3.6M | 2.6% |
DMRADamora Therapeutics, Inc. | 139K | ±0% | $3.6M | 2.6% |
MLTXMoonLake Immunotherapeutics | 175.7K | ±0% | $3.4M | 2.5% |
TYRATyra Biosciences, Inc. | 74.5K | ±0% | $2.4M | 1.7% |
NVCTNuvectis Pharma, Inc. | 100K | New | $1.8M | 1.3% |
GOSSGossamer Bio, Inc. | 11.1M | +49.2% | $1.8M | 1.3% |
MISTMilestone Pharmaceuticals Inc. | 1.3M | New | $1.7M | 1.2% |
ATYRaTYR PHARMA INC | 1.8M | New | $1.1M | 0.8% |
TILInstil Bio, Inc. | 99.6K | −28.8% | $765.9K | 0.5% |
TCRXTScan Therapeutics, Inc. | 454.9K | New | $445.8K | 0.3% |
